Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report

    September 2025 in “ Asian journal of pediatric dermatology. ”
    Aira Louise Espinar Empaynado, Arnelfa Co Paliza
    Studysummary This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up Journal of asthma and allergy · 2024
    2. Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib Journal of cosmetic dermatology · 2023
    3. Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata Skin health and disease · 2023
    4. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    5. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018